Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Results of Operations and Financial Condition

Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02

On March 16, 2020, Fortress Biotech, Inc. issued a press release to announce financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2019. A copy of such press release is being furnished as Exhibit 99.1 to this report.

99.1 Press release issued by Fortress Biotech, Inc., dated March 16, 2020. 

Fortress Biotech, Inc. Exhibit
EX-99.1 2 tm2012819d1_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights   Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2019 compared to 2018   NDA for IV tramadol accepted for review by FDA; PDUFA date is set for October 10,…
To view the full exhibit click here

Story continues below

About Fortress Biotech, Inc. (NASDAQ:FBIO)

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

An ad to help with our costs